Two dosage interferon-alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial. 1998

M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
Clinica di Ematologia, Ancona University, Ospedale Torrette, Torrette di Ancona, Italy.

OBJECTIVE The role of interferon (IFN) in the remission phase of multiple myeloma (MM) is still an open question, particularly for its scheduling and the subset of patients who could benefit from this approach. The present randomized multicenter study was designed to compare two schedules of IFN maintenance therapy in order to assess the difference in effectiveness and tolerance. METHODS This prospective randomized multicenter study was attempted to assess the best schedule of IFN administration in the maintenance treatment of MM in plateau phase with regard to progression free survival (PFS) and toxicity. The second aim was defining the difference between the two schedules in overall survival (OS) and identifying the critical dose of IFN therapy needed to prolong plateau phase and survival. We enrolled 52 patients affected with low-risk MM (i.e. with serum beta 2-microglobulin < 6.0 mg/L and serum albumin > 3.0 g/dL); 27 patients (group A) were randomly assigned to receive IFN alpha-2b 3 megaunits (MU) subcutaneously three times a week and 25 patients (group B) 3 MU/day until disease progression. RESULTS Median progression free survival (PFS) was 11.9 months in group A and 38.3 months in group B (p = 0.0038). Median survival was 63.2 months in group A and 61.9 months in group B (p = 0.489). However, those patients who were given an IFN dose > or = 30 MU/month experienced a significantly longer PFS and survival than the other patients. Seventeen patients (32.7%) discontinued therapy and sixteen patients (30.8%) reduced IFN alpha-2b dose because of severe side effects without having a significant difference between the two schedules. CONCLUSIONS Our results show that patients treated with IFN alpha 3 MU/day had a significantly longer remission duration than patients treated with IFN alpha 3 MU three times weekly. Moreover, an IFN dose is probably critical for obtaining a longer survival in patients affected with low-risk MM. Since the patients' discomfort during a IFN maintenance therapy was frequently experienced the quality of their lives should be carefully taken into account.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
March 1995, British journal of haematology,
M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
October 1994, British journal of cancer,
M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
August 1992, European journal of haematology,
M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
January 1996, Annals of internal medicine,
M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
January 1990, European journal of haematology. Supplementum,
M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
April 2005, Annals of oncology : official journal of the European Society for Medical Oncology,
M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
December 2005, Annals of oncology : official journal of the European Society for Medical Oncology,
M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
November 2000, American journal of hematology,
M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
April 1998, British journal of haematology,
M Offidani, and A Olivieri, and M Montillo, and S Rupoli, and R Centurioni, and F Alesiani, and G Marchegiani, and S Pieroni, and M Catarini, and G Pelliccia, and F Altilia, and P Leoni
February 2009, Melanoma research,
Copied contents to your clipboard!